LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

PTC Therapeutics Inc

Closed

SectorHealthcare

52.31 6.04

Overview

Share price change

24h

Current

Min

49.33

Max

52.96

Key metrics

By Trading Economics

Income

-931M

-65M

Sales

-997M

179M

P/E

Sector Avg

6.993

35.724

Profit margin

-36.254

Employees

939

EBITDA

-1B

-35M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+32.84% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-225M

3.9B

Previous open

46.27

Previous close

52.31

News Sentiment

By Acuity

50%

50%

167 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

PTC Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2025, 16:40 UTC

Major Market Movers

PTC Therapeutics Gains on FDA Approval for Blood-Disorder Treatment

2 Dec 2024, 12:47 UTC

Major Market Movers

PTC Therapeutics Shares Jump on Pact With Novartis

Peer Comparison

Price change

PTC Therapeutics Inc Forecast

Price Target

By TipRanks

32.84% upside

12 Months Forecast

Average 65.53 USD  32.84%

High 120 USD

Low 44 USD

Based on 17 Wall Street analysts offering 12 month price targets forPTC Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

11

Buy

5

Hold

1

Sell

Technical Score

By Trading Central

40.81 / 50.39Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

167 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.